Before PSM, the trends of selection of no adjuvant WBRT (raw population in Table 1) were compatible with those in previous studies, in which women with node-negative, hormone receptor-positive, HER2-negative cancer or small tumor sizes preferred no adjuvant RT [8,9,10,11,12]. The gene discussed is ERBB2; the disease is cancer.